Entrada Therapeutics, Inc. (TRDA)
Largest Insider Buys in Sector
TRDA Stock Price History Chart
TRDA Stock Performance
About Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company …
Insider Activity of Entrada Therapeutics, Inc.
Over the last 12 months, insiders at Entrada Therapeutics, Inc. have bought $641,939 and sold $1.36M worth of Entrada Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Entrada Therapeutics, Inc. have bought $24.62M and sold $2.33M worth of stock each year.
Highest buying activity among insiders over the last 12 months: KIM PETER S (director) — $1.28M.
The last purchase of 25,000 shares for transaction amount of $364,673 was made by KIM PETER S (director) on 2024‑05‑14.
List of Insider Buy and Sell Transactions, Entrada Therapeutics, Inc.
| 2024-10-16 | Sale | President, Research & Develop. | 600 0.0018% | $18.00 | $10,800 | -1.59% | ||
| 2024-09-26 | Sale | President & COO | 847 0.0025% | $16.00 | $13,552 | 0.00% | ||
| 2024-09-09 | Sale | Chief Scientific Officer | 2,642 0.0071% | $15.09 | $39,862 | +9.38% | ||
| 2024-09-09 | Sale | President & COO | 1,904 0.0051% | $15.07 | $28,690 | +9.38% | ||
| 2024-09-09 | Sale | Chief Financial Officer | 3,195 0.0086% | $14.97 | $47,832 | +9.38% | ||
| 2024-09-06 | Sale | Chief Scientific Officer | 600 0.0017% | $15.24 | $9,141 | +10.91% | ||
| 2024-09-06 | Sale | President & COO | 399 0.0011% | $15.19 | $6,063 | +10.91% | ||
| 2024-08-16 | Sale | President & COO | 27,097 0.0841% | $16.27 | $440,801 | 0.00% | ||
| 2024-07-15 | Sale | CEO | 1,600 0.006% | $17.81 | $28,497 | 0.00% | ||
| 2024-07-15 | Sale | Chief Scientific Officer | 638 0.0024% | $18.00 | $11,484 | 0.00% | ||
| 2024-07-12 | Sale | CEO | 300 0.0011% | $18.00 | $5,400 | 0.00% | ||
| 2024-07-12 | Sale | Chief Scientific Officer | 600 0.0023% | $18.00 | $10,800 | 0.00% | ||
| 2024-07-08 | Sale | Chief Financial Officer | 1,758 0.0055% | $14.95 | $26,282 | 0.00% | ||
| 2024-06-13 | Sale | CEO | 1,000 0.0031% | $16.17 | $16,174 | -1.34% | ||
| 2024-05-20 | Sale | Chief Scientific Officer | 9,675 0.0284% | $15.19 | $146,944 | +4.18% | ||
| 2024-05-17 | Sale | CEO | 1,200 0.0036% | $15.11 | $18,129 | +6.20% | ||
| 2024-05-17 | Sale | Chief Scientific Officer | 8,305 0.0253% | $15.14 | $125,751 | +6.20% | ||
| 2024-05-16 | Sale | CEO | 1,800 0.0054% | $15.00 | $27,000 | +6.36% | ||
| 2024-05-16 | Sale | Chief Scientific Officer | 1,000 0.003% | $15.00 | $15,000 | +6.36% | ||
| 2024-05-14 | director | 25,000 0.0761% | $14.59 | $364,673 | +11.50% |
Insider Historical Profitability
| KIM PETER S | director | 92412 0.2484% | $18.56 | 11 | 0 | |
| BAKER BROS. ADVISORS LP | 10 percent owner | 4501658 12.1014% | $18.56 | 8 | 0 | +124.37% |
| Baker Bros. Advisors (GP) LLC | 4475208 12.0303% | $18.56 | 3 | 0 | +129.14% | |
| Foley Todd | 4425784 11.8974% | $18.56 | 1 | 0 | <0.0001% | |
| MPM BioVentures 2014, L.P. | 10 percent owner | 4425784 11.8974% | $18.56 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Baker Bros Advisors LP | $68.95M | 13.16 | 4.87M | 0% | +$0 | 0.5 | |
| MPM Asset Management LLC | $62.71M | 11.97 | 4.43M | 0% | +$0 | 25.58 | |
| 5Am Venture Management Llc | $62.47M | 11.92 | 4.41M | 0% | +$0 | 4.19 | |
| T. Rowe Price | $39.02M | 7.45 | 2.75M | -8.52% | -$3.63M | 0.01 | |
| BlackRock | $21.06M | 4.02 | 1.49M | -1.09% | -$231,948.75 | <0.0001 |